title: Hormone replacement therapy and urinary prostaglandins in postmenopausal women.
abstract: The objective of the study was to observe the effects of hormone replacement therapy upon urinary prostaglandin E2 and prostaglandin F2 alpha levels in postmenopausal patients. A total number of 55 women were enrolled in this study and 15 premenopausal (PreM) healthy subjects constitute the control group. A total of 40 patients at least 12 months after their natural menopause were divided into two groups: 15 of them was not medicated hormone replacement therapy (which composed NRHRT group) while 25 of the rest, received conjugated estrogen (Premarin) 0.625 mg/day orally plus medroxyprogesterone acetate (Farlutal) 10 mg/day orally built up the RHRT group. PGE2 and PGF2 alpha levels were measured with PGE2 [125I] and PGF2 alpha [3H] RIA kits. Statistical significance was analyzed by Student's t-test for impaired data. NRHRT and RHRT patients had had increased urinary PGE2 levels when compared with PreM (P < 0.001). HRT caused a significant decrease in PGE2 levels in menopausal women (P < 0.001). Urinary PGF2 alpha values of NRHRT and RHRT were significantly lower (P < 0.001) in comparison with PreM group. There was no difference in PGF2 alpha values between two postmenopausal groups. HRT given to postmenopausal patients might have a positive impact on prostaglandins and therefore on bone turnover in a series of various mechanisms.
authors.affiliation: Department of Obstetrics and Gynecology, Istanbul Medical Faculty, Turkey.
authors.forename: C
authors.initials: C
authors.lastname: Akgül
authors.forename: M
authors.initials: M
authors.lastname: Canbaz
authors.forename: P
authors.initials: P
authors.lastname: Vural
authors.forename: A
authors.initials: A
authors.lastname: Yildirim
authors.forename: N
authors.initials: N
authors.lastname: Geren
mesh_terms: D000328:Adult; D015237:Dinoprost / Q000652:urine*; D015232:Dinoprostone / Q000652:urine*; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology*; D005260:Female; D020249:Hormone Replacement Therapy; D006801:Humans; D017258:Medroxyprogesterone Acetate / Q000494:pharmacology*; D008875:Middle Aged; D017698:Postmenopause; D045167:Progesterone Congeners / Q000494:pharmacology*
chemical_list: D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D015237:Dinoprost; D017258:Medroxyprogesterone Acetate; D015232:Dinoprostone